|
gptkbp:instanceOf
|
gptkb:inotropic_agent
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:European_Union
|
|
gptkbp:ATCCode
|
C01CX08
|
|
gptkbp:bioavailability
|
intravenous only
|
|
gptkbp:CASNumber
|
141505-33-1
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
severe renal impairment
severe hepatic impairment
severe hypotension
|
|
gptkbp:developedBy
|
gptkb:Orion_Pharma
|
|
gptkbp:discoveredIn
|
1990s
|
|
gptkbp:drugClass
|
cardiotonic agent
|
|
gptkbp:eliminationHalfLife
|
about 1 hour (parent drug)
about 80 hours (active metabolite)
|
|
gptkbp:hasMolecularFormula
|
C14H12N6O
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:potassium_channel_opener
calcium sensitizer
|
|
gptkbp:metabolism
|
OR-1855
OR-1896
|
|
gptkbp:molecularWeight
|
280.29 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:proteinBinding
|
97-98%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
headache
hypotension
|
|
gptkbp:synonym
|
gptkb:Simdax
|
|
gptkbp:usedFor
|
acute decompensated heart failure
|
|
gptkbp:bfsParent
|
gptkb:Simdax
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
levosimendan
|